Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

TENDU Vaccine in Patients With Relapse After Primary Radical Prostatectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04701021
Recruitment Status : Recruiting
First Posted : January 8, 2021
Last Update Posted : February 21, 2021
Sponsor:
Information provided by (Responsible Party):
Ultimovacs ASA

Brief Summary:
This is a phase I, dose selection study of safety and effect of different doses of TENDU vaccine, a therapeutic peptide conjugate vaccine, in patients with relapse after primary radical prostatectomy.

Condition or disease Intervention/treatment Phase
Prostate Cancer Biological: TENDU Phase 1

Detailed Description:

This is a open label dose selection study to investigate the safety, tolerability, immune response and preliminary clinical effect of different doses of the TENDU vaccine. TENDU is a synthetic therapeutic peptide conjugate vaccine intended for treatment of prostate cancer.

The patients enrolled in this study is adults with documented progressive disease after radical prostatectomy and who are eligible for salvage radiotherapy and short-term (6 months) androgen deprivation therapy.

All patients taking part at the study must be vaccinated with a Boostrix vaccine (including tetanus antigen) one week prior to the first TENDU vaccine treatment.

Three different doses, 40, 400 and 960 μg of the TENDU vaccine are to be investigated.

The vaccine is administrated by subcutaneous injections with one injection per drug substance (four separate injections) consecutively. The TENDU vaccine will be given four times during a treatment period lasting for 6 weeks and followed up for 6 months after the last treatment.

In total between 12 to 18 patients will be enrolled with a 3+3 design in each dose cohort. The first patient will receive the lowest dose of the TENDU vaccine, and after the treatment is completed, a safety evaluation will be done to evaluate enrolment of the next patients in this cohort. If one patient develops a dose limiting toxicity at a specific dose, an additional three patients are to be enrolled into that same dose cohort, and on the recommended dose an addition of 3 patients will be enrolled.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Effect of Different Doses of TENDU Vaccine, a Therapeutic Peptide Conjugate Vaccine, in Patients With Relapse After Primary Radical Prostatectomy
Actual Study Start Date : February 17, 2021
Estimated Primary Completion Date : July 31, 2022
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: TENDU
Three different doses of the TENDU vaccine are to be investigated: 40, 400 and 960μg.
Biological: TENDU
The vaccine is administrated by subcutaneous injections, one injection per drug substance (four separate injections) consecutively.




Primary Outcome Measures :
  1. Assessment of safety and tolerability of TENDU vaccine [ Time Frame: Time from enrollment until 6 months after last dose ]
    Frequency and severity of Adverse Events (AEs) graded according to CTCAE version 5.0.


Secondary Outcome Measures :
  1. Assessment of Immunological response [ Time Frame: Time from enrollment until 6 months after last dose ]
    To evaluate the immunological response against the prostate specific peptides in the patients at baseline and after TENDU vaccinations.

  2. Assessment of anti-tetanus protein and anti-MTTE titers [ Time Frame: Time from enrollment until 6 months after last dose ]
    To evaluate the preliminary anti-tumor activity of the TENDU vaccine in patients pre- and post the vaccination with Boostrix (including tetanus antigen) and the TENDU vaccinations by evaluation of anti-tetanus protein and anti-MTTE titers.

  3. Assessment of Anti-tumor activity [ Time Frame: Time from enrollment until 6 months after last dose ]
    To evaluate the preliminary anti-tumor activity of the TENDU vaccine according to changes in the PSA, PAP, PSMA and PET/CT.


Other Outcome Measures:
  1. Assessment of antibody titers [ Time Frame: Time from enrollment until 6 months after last dose ]
    Evaluation of antibody titers against PAP and PSMA peptides epitopes presented in the TENDU vaccine.

  2. Assessment of possible biomarkers [ Time Frame: Time from enrollment until 6 months after last dose ]
    Assessment of possible biomarkers e.g. phenotyping of circulating tumor cells (CTCs)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males ≥18 years of age
  2. PSA rise >0.2 ng/mL less than 18 months following radical prostatectomy (RP) and pathological ISUP Grade 4-5 (Gleason score >7), or persisting PSA >0.1 ng/mL six weeks after RP and short PSA-DT, eligible for salvage radiotherapy and short term androgen deprivation therapy
  3. ECOG performance status 0 or 1
  4. Adequate organ function as indicated by the following laboratory values:

    • White blood cell count ≥ 2,500/μL
    • Absolute neutrophil count ≥ 1,000/μL
    • Platelets ≥ 100,000/μL
    • Haemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L
    • Serum creatinine ≤ 1.5 x upper limit of normal (ULN)
    • Serum total bilirubin ≤ 1.5 x ULN or direct bilirubin ≤ ULN for patients with total bilirubin levels > 1.5 ULN
    • AST and ALT ≤ 2.5 x ULN
  5. Patients with potential to father children must use an acceptable contraceptive method
  6. Written informed consent prior to any study-specific evaluations

Exclusion Criteria:

  1. History of hematologic or primary solid tumor malignancy other than prostate cancer with remission less than 3 years prior study enrolment.
  2. Metastatic disease assessed by PSMA PET/CT
  3. Hypersensitivity to the active substance or any of its excipients
  4. Current use of androgen deprivation therapy or radiotherapy to the pelvis
  5. Known history or any evidence of active, non-infectious pneumonitis
  6. History of New York Heart Association class 3-4 congestive heart failure or history of myocardial infarction within 6 months of starting study treatment
  7. Active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Patients with vitiligo or resolved childhood asthma/atopy would be an exception to this rule.
  8. Active infection requiring systemic therapy
  9. Diagnosis of immunodeficiency
  10. Any use of immunosuppressive (cytotoxic chemotherapy, systemic steroids) or immunomodulating agents within 8 weeks of study entry.
  11. Hepatitis B or Hepatitis C or Human Immunodeficiency Virus positive
  12. Expected to require any other form of systemic or localized antineoplastic therapy during the study
  13. Received any other investigational therapy within 4 weeks of the first dose of study treatment
  14. Any medical, psychological, social or neurological condition that would make it difficult for the patient to participate in the study and comply with the study procedures, restrictions, and requirements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04701021


Contacts
Layout table for location contacts
Contact: Wenche Rasch, PhD +4740062030 wenche.rasch@ultimovacs.com

Locations
Layout table for location information
Norway
Oslo University Hospital, The Norwegian Radium Hospital Recruiting
Oslo, Norway, 0379
Sponsors and Collaborators
Ultimovacs ASA
Investigators
Layout table for investigator information
Principal Investigator: Wolfgang Lilleby, MD PhD Oslo universitetssykehus HF
Layout table for additonal information
Responsible Party: Ultimovacs ASA
ClinicalTrials.gov Identifier: NCT04701021    
Other Study ID Numbers: TENDU-101
First Posted: January 8, 2021    Key Record Dates
Last Update Posted: February 21, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ultimovacs ASA:
prostate
vaccine
cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Recurrence
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases
Disease Attributes
Pathologic Processes